Daily Endocrinology Research Analysis
Three papers stood out today across endocrinology and metabolism: a Science Advances study reveals phosphorylation-dependent assembly of the ChREBP–MLX complex that governs carbohydrate/lipid gene programs; a Diabetologia human study links clustered pancreatic adipocytes to beta-cell dedifferentiation in type 2 diabetes; and a Clinical Pharmacology & Therapeutics meta-analysis plus Mendelian randomization quantifies diabetic ketoacidosis risk with SGLT2 inhibitors and identifies high-risk subgro
Summary
Three papers stood out today across endocrinology and metabolism: a Science Advances study reveals phosphorylation-dependent assembly of the ChREBP–MLX complex that governs carbohydrate/lipid gene programs; a Diabetologia human study links clustered pancreatic adipocytes to beta-cell dedifferentiation in type 2 diabetes; and a Clinical Pharmacology & Therapeutics meta-analysis plus Mendelian randomization quantifies diabetic ketoacidosis risk with SGLT2 inhibitors and identifies high-risk subgroups.
Research Themes
- Transcriptional control of glucose and lipid metabolism
- Pancreatic fat and beta-cell dedifferentiation in type 2 diabetes
- Drug safety stratification for SGLT2 inhibitors and DKA risk
Selected Articles
1. MLX phosphorylation stabilizes the ChREBP-MLX heterotetramer on tandem E-boxes to control carbohydrate and lipid metabolism.
This mechanistic study demonstrates that phosphorylation of MLX by CK2 and GSK3 is required to assemble and stabilize the ChREBP–MLX heterotetramer on ChoREs, enabling carbohydrate/lipid gene transcription. Elevated glucose-6-phosphate inhibits MLX phosphorylation, dampening ChREBP–MLX activity.
Impact: It uncovers a previously unrecognized regulatory switch for a central nutrient-sensing transcriptional complex, offering new targets (CK2/GSK3–MLX axis) to modulate hepatic and adipose metabolism.
Clinical Implications: While preclinical, the CK2/GSK3–MLX phosphorylation axis could be leveraged to fine-tune ChREBP activity in conditions such as nonalcoholic fatty liver disease, hypertriglyceridemia, and type 2 diabetes.
Key Findings
- MLX phosphorylation on a conserved motif is necessary for ChREBP–MLX heterotetramer assembly on ChoREs and for downstream transcriptional activity.
- CK2 and GSK3 are identified as MLX kinases; their action stabilizes the heterotetramer.
- High intracellular glucose-6-phosphate inhibits MLX phosphorylation and impairs ChREBP–MLX function.
Methodological Strengths
- Identification of specific kinases (CK2, GSK3) and a conserved phosphorylation motif linking post-translational modification to complex assembly.
- Mechanistic dissection of nutrient (G6P)-dependent modulation of transcription factor complex formation.
Limitations
- Abstract suggests incomplete physiological validation details; disease-model efficacy and in vivo metabolic outcomes are not described.
- Translational relevance to specific tissues and human pathophysiology requires further work.
Future Directions: Define tissue-specific MLX phosphorylation dynamics in vivo, test pharmacologic modulation of CK2/GSK3–MLX in metabolic disease models, and map genome-wide ChoRE occupancy under altered phosphorylation.
Carbohydrate-responsive element binding protein (ChREBP) and Max-like protein X (MLX) form a heterodimeric transcription factor complex that couples intracellular sugar levels to carbohydrate and lipid metabolism. To promote the expression of target genes, two ChREBP-MLX heterodimers form a heterotetramer to bind a tandem element with two adjacent E-boxes, called carbohydrate-responsive element (ChoRE). How the ChREBP-MLX hetero-tetramerization is achieved and regulated remains poorly understood. Here, we show that MLX phosphorylation on an evolutionarily conserved motif is necessary for the heterotetramer formation on the ChoRE and the transcriptional activity of the ChREBP-MLX complex. We identified casein kinase 2 (CK2) and glycogen synthase kinase 3 (GSK3) as MLX kinases. High intracellular glucose-6-phosphate accumulation inhibits MLX phosphorylation and heterotetramer formation on the ChoRE, impairing ChREBP-MLX activity. Physiologically, MLX phosphorylation is necessary in
2. Sodium-Glucose Cotransporter-2 Inhibitors and Diabetic-Ketoacidosis in T2DM Patients: An Updated Meta-Analysis and a Mendelian Randomization Analysis.
Across 80,235 participants in 22 RCTs, SGLT2 inhibitors doubled DKA risk overall (RR 2.32), with signal concentrated at higher HbA1c, in CKD, and high ASCVD-risk trials, but not significantly in heart failure trials. Mendelian randomization supported a genetic association with DKA liability.
Impact: Provides rigorous, subgroup-resolved quantification of DKA risk, informing clinical risk stratification and monitoring when prescribing SGLT2 inhibitors in T2DM.
Clinical Implications: Consider enhanced patient education and ketone monitoring in T2DM patients with high HbA1c, CKD, or high ASCVD risk starting SGLT2 inhibitors; risk appears lower in heart failure populations.
Key Findings
- SGLT2 inhibitors increased DKA risk versus controls across 22 RCTs (RR 2.32; 95% CI 1.64–3.27).
- Risk elevation was significant at HbA1c >7.9% and in CKD or high ASCVD risk trials, but not significant in heart failure trials.
- Mendelian randomization supported a genetic association between SGLT2i use and DKA risk.
Methodological Strengths
- Large-scale meta-analysis of randomized trials with predefined subgroup analyses (HbA1c, CKD, ASCVD, HF).
- Triangulation with Mendelian randomization to mitigate confounding and strengthen causal inference.
Limitations
- DKA is a rare outcome; event adjudication and reporting may vary across trials.
- MR relies on instrument validity assumptions and reflects lifetime exposure proxies rather than trial-like interventions.
Future Directions: Develop risk scores integrating HbA1c, renal function, and ASCVD status to personalize SGLT2i safety monitoring; assess preventive strategies (e.g., sick-day rules, ketone education) in high-risk T2DM subgroups.
To evaluate the association of sodium-glucose cotransporter 2 inhibitors (SGLT2i) with diabetic ketoacidosis (DKA) in type 2 diabetes mellitus (T2DM) patients across different subgroups, we searched randomized controlled trials (RCTs) comparing SGLT2i with the control groups among T2DM patients and including DKA as a safety outcome. Pooled risk ratios (RRs) were calculated using random or fixed-effects models, as appropriate. An inverse-variance-weighted Mendelian randomization (MR) analysis was performed to estimate the genetic correlation. Twenty-two trials involving 80,235 patients were included. SGLT2i increased the risk of DKA compared to the control groups (RR 2.32, 95% CI 1.64-3.27). The risk was significantly increased in patients with higher HbA1c levels (> 7.9%) (RR 2.24, 95% CI 1.59-3.14), but not in those with lower HbA1c levels (≤ 7.9%) (RR 1.05, 95% CI 0.49-2.26; interaction P = 0.034). SGLT2i increased DKA risk in chronic kidney disease (CKD) (RR 2.70, 95% CI 1.55-4.71) and high atherosclerotic cardiovascular disease (ASCVD) risk trials (RR 2.46, 95% CI 1.47-4.11) but not significantly in heart failure (HF) trials (RR 1.23, 95% CI 0.51-2.96). Moreover, in the HF trials, SGLT2i consistently did not increase the risk of DKA in any clinical subgroups. Nevertheless, MR analysis still confirmed a genetic association between SGLT2i and the risk of DKA among overall T2DM patients. SGLT2i may increase the risk of DKA in T2DM patients, particularly in patients with higher levels of HbA1c and those with comorbid CKD or at high-risk ASCVD. However, the increased risk was not significant in patients with HF.
3. Intrapancreatic adipocytes and beta cell dedifferentiation in human type 2 diabetes.
In human donor pancreases, higher pancreatic fat—particularly adipocyte clustering—was linked to reduced beta-cell mass, higher alpha:beta ratios, increased ALDH1A3 expression, and transcriptomic signatures of beta-cell dedifferentiation and transdifferentiation toward alpha cells, alongside inflammatory pathway activation.
Impact: Provides human evidence connecting pancreatic adiposity to immune recruitment and beta-cell fate changes, reframing pancreatic fat as an active microenvironmental driver of beta-cell failure.
Clinical Implications: Highlights pancreatic fat as a potential therapeutic target; motivates imaging/biomarker strategies to identify patients with high intrapancreatic adiposity who may benefit from interventions reducing ectopic fat and inflammation.
Key Findings
- Pancreatic fat content was higher in T2D (median ~10%) versus non-diabetic donors (~0.7%) and inversely correlated with estimated beta-cell mass (r = -0.675).
- High pancreatic fat associated with increased ALDH1A3 expression (dedifferentiation marker), reduced NPY, and pseudotime evidence of beta-cell dedifferentiation/transdifferentiation toward alpha cells.
- Adipocyte clusters correlated with T-cell proximity and inflammatory pathway activation, linking adiposity to immune recruitment and islet remodeling.
Methodological Strengths
- Integration of human histology (n=50) with single-cell RNA-seq (n=11 T2D donors) and spatial correlations.
- Use of dedifferentiation markers (ALDH1A3) and pseudotime analyses to infer beta-cell fate changes.
Limitations
- Cross-sectional donor study limits causal inference; confounding by donor characteristics is possible.
- Single-cell dataset size is modest; functional interventional validation is lacking.
Future Directions: Test whether reducing intrapancreatic adiposity and local inflammation reverses dedifferentiation; develop noninvasive imaging/serologic markers of pancreatic fat clustering and islet immune activation.
AIMS/HYPOTHESIS: Fat deposition in the pancreas is implicated in beta cell dysfunction and the progress of type 2 diabetes. However, there is limited evidence to confirm the correlation and explore how pancreatic fat links with beta cell dysfunction in human type 2 diabetes. This study aimed to examine the spatial relationship between pancreatic fat and islets in human pancreases. METHODS: Histological analysis of pancreatic specimens from 50 organ donors (15 with type 2 diabetes, 35 without) assessed pancreatic fat content variation among individuals with diabetes and its correlation with estimated beta cell mass and cell distribution within islets. Bioinformatic analysis of single-cell RNA-seq of 11 type 2 diabetic donors (from the Human Pancreatic Analysis Project database) explored the impact of high pancreatic fat content on beta cell gene expression and cell fate. Validation of bioinformatic results was performed with the above diabetic pancreases. RESULTS: Pancreatic fat content was higher in individuals with type 2 diabetes (10.24% [3.29-13.89%] vs 0.74% [0.34-5.11%], p<0.001), negatively correlated with estimated beta cell mass (r=-0.675, p=0.006) and positively with alpha-to-beta cell ratio (r=0.608, p=0.016). Enrichment analysis indicated that in diabetic donors with higher pancreatic fat content, the expression of ALDH1A3, beta cell dedifferentiation marker, in both alpha and beta cells was significantly increased, and in beta cells, the expression of NPY decreased. Pseudotime analysis revealed beta cell dedifferentiation and transdifferentiation towards alpha cells in diabetic donors with higher pancreatic fat content, with decreased expression of genes related to beta cell maturation and function, including INSM1, MafA and NPY. Concurrently, pathways related to inflammation and immune response were activated. Histologically, pancreatic fat content correlated positively with the percentage of beta cells positive for aldehyde dehydrogenase 1 family member A3 (ALDH1A3) within the islets (r=0.594, p=0.020) and the ALDH1A3 positivity rate in beta cells (r=0.615, p=0.015). And the number of T cells adjacent to adipocytes was related to the distribution pattern of adipocytes and the dedifferentiation phenotype in islets. CONCLUSIONS/INTERPRETATION: Higher pancreatic fat content was accompanied by increased beta cell dedifferentiation in the individuals with diabetes. Clusters of adipocytes significantly contribute to higher pancreatic fat content and immune cell recruitment. Overall, the interactions among adipocytes, immune cells and beta cells in the pancreas microenvironment might contribute to beta cell failure and dedifferentiation in type 2 diabetes.